Journal of Bioequivalence & Bioavailability

Penelope Stiefel

Publications

• Research Article
  Use of Recombinant Factor VIIA as a Risk Factor for Graft Loss after Orthotopic Liver Transplantation Due to Hepatic Artery Thrombosis
  Author(s): Fabian A Helfritz, Penelope Stiefel, Michael P Manns, Jürgen Klempnauer, Frank Lehner, Henrike Lenzen and Sandra CiesekFabian A Helfritz, Penelope Stiefel, Michael P Manns, Jürgen Klempnauer, Frank Lehner, Henrike Lenzen and Sandra Ciesek
  
  Background: The genetically engineered recombinant activated factor VII (rFVIIa) was primarily developed for the treatment of bleeding episodes in haemophilia patients with inhibitors. Different outcomes have been described in a number of studies evaluating the off-label use in patients with liver disease and consequently with complex coagulopathies. We here evaluated the use of rFVIIa in patients undergoing orthotopic liver transplantation (OLT). The aim of this study was to determine the safety within this patient population. Methods: Overall, 1343 OLTs were performed at Hannover Medical School between 2002 and 2014. Out of this group we selected patients having received rFVIIa in the early phase after OLT. We retrospectively analyzed the outcome of patients treated with rFVIIa and compared our findings to those from other transplant centers. .. View More»
  DOI: 10.4172/jbb.1000259

  Abstract PDF